Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

Mechanism / theoretical grounding — not clinical validation.

Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IY. Bull Exp Biol Med. 2002.

Organ: general-aging · Type: in-vitro · Peptides: Livagen

PMID: 12533768

In cultured lymphocytes from elderly donors, Livagen was reported to activate ribosomal genes and decondense heterochromatin — a cytogenetic culture paper, not a clinical trial.

Editorial summary of a 2002 original article in Bulletin of Experimental Biology and Medicine. Lymphocyte chromatin work with the synthetic peptide Livagen (KEDA). Public pages cite PubMed only. Read the paper: PMID 12533768.

Methods

The authors studied Livagen in lymphocytes from old people, reporting activity of ribosomal genes, denaturation parameters of heterochromatin, polymorphism of structural C-heterochromatin, and variability of facultative heterochromatin. Donor counts, peptide concentration, and culture times are not given in the English abstract; those details belong in the primary text. This is cultured-cell cytogenetics, not an administered-patient protocol.

Findings

This paper is mechanistic or modeling evidence, not a clinical trial. The authors report that Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes they attribute to age-related condensation of euchromatic chromosome regions. They interpret this as de-heterochromatinization (activation) of chromatin in lymphocytes from old people.

Elderly-donor lymphocytes in culture are not a clinical trial of Livagen. Follow the PMID.